{"entity":{"id":"olaparib","kind":"drug","name":"Olaparib","aka":[],"tldr":"Olaparib was the first PARP inhibitor, and turned an inherited BRCA mutation from a risk factor into a drug target, including after surgery in breast cancer.","summary":"Approved 2014 (ovarian), then maintenance first-line (SOLO-1, 7-year OS benefit), with bevacizumab (PAOLA-1, HRD+), metastatic BRCA breast (OlympiAD), adjuvant germline-BRCA HER2-negative early breast cancer (OlympiA, OS HR 0.72), pancreatic maintenance (POLO), and prostate (PROfound; PROpel with abiraterone). AstraZeneca/Merck.","status":"approved","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Olaparib","links":[{"label":"FDA label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Olaparib"},{"label":"NICE TA886: olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer (10 May 2023)","url":"https://www.nice.org.uk/guidance/ta886"},{"label":"NICE TA1040: olaparib for BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy (12 February 2025)","url":"https://www.nice.org.uk/guidance/ta1040"},{"label":"Lynparza label (openFDA): OlympiA and OlympiAD study sections","url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22LYNPARZA%22"},{"label":"Kindler et al., POLO overall survival (JCO 2022)","url":"https://doi.org/10.1200/JCO.21.01604"},{"label":"NICE TA887: olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer","url":"https://www.nice.org.uk/guidance/ta887"},{"label":"NICE TA951: olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer","url":"https://www.nice.org.uk/guidance/ta951"}],"tags":[],"related":["brca-germline","brca-somatic","hrd-positive"],"cancers":["ovarian","tnbc","breast-hr-positive","prostate","pancreatic","high-grade-serous-ovarian-cancer","prostate-mcrpc","tnbc-early","tnbc-metastatic","platinum-sensitive-ovarian-cancer","brca-palb2-pdac"],"sections":[],"technologies":["parp-inhibitor"],"targets":["parp","brca"],"drugs":[],"companies":["astrazeneca","merck"],"institutions":[],"pathways":[],"terms":["prostate-hrr-eligibility","prostate-uk-drug-approvals"],"trials":["olympia","nct04884360","nct04421963","nct04624204","nct05171816","nct06915025","nct01081951","nct06686030","nct07024784","nct04644289","nct03775486","nct02861573","nct06909825","nct05898399","nct06525298","nct05498155","nct01874353","nct02734004","nct03742895","nct06353386","nct03459846","nct04380636","partner","phoenix","nct06112379","polo"],"people":[],"bottlenecks":[],"keyPapers":["paper-olympia-nejm-2021","paper-couch-tnbc-germline-17-genes-jco-2015","paper-bedrosian-asco-sso-germline-testing-breast-jco-2024","paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019","paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022","paper-hu-germline-mutations-pancreatic-cancer-risk-jama-2018"],"journals":[],"dependsOn":[],"notes":["Triple-negative breast cancer: eligibility is germline BRCA1/2 by blood test, present in about 11 to 17% of TNBC (Couch 2015, Hahnen 2017); somatic-only or HRD-positive results do not qualify under the breast labels.","Triple-negative breast cancer: 82 percent of OlympiA patients had triple-negative disease (Lynparza label), so the adjuvant indication is in practice a triple-negative one; about half of OlympiAD patients were triple-negative, and in the OlympiAD final overall survival analysis the triple-negative subgroup hazard ratio was 0.93 (0.62 to 1.43). OlympiA recruited at 22 UK sites. The UK-led PARTNER trial (30 NHS hospitals) tests olaparib added to neoadjuvant carboplatin and paclitaxel in triple-negative or germline BRCA breast cancer.","Pancreatic cancer, UK status: NICE's appraisal of olaparib for pancreatic cancer (TA750) was terminated on 8 December 2021 because AstraZeneca made no evidence submission (its published olaparib appraisals cover ovarian, breast, prostate and endometrial cancer), so maintenance olaparib for germline BRCA carriers is not routinely commissioned in England although the drug is licensed for the use in the EU and UK. POLO label figures: progression-free survival 7.4 against 3.8 months (hazard ratio 0.53; p 0.0035), overall survival 19.0 against 19.2 months (hazard ratio 0.83; p 0.3487), response 23 against 12 percent with a median duration of 25 against 4 months; 75 percent of patients had received FOLFIRINOX; nine UK sites (Edinburgh, Glasgow, Liverpool, London, Manchester, Northwood, Nottingham, Surrey).","Pancreatic ductal adenocarcinoma biomarkers: eligibility is a germline BRCA1 or BRCA2 variant, present in about 2 to 3% of patients, plus at least 16 weeks of first-line platinum without progression (POLO). Somatic BRCA, PALB2 and genomic instability scores do not qualify under the label, although rucaparib showed activity in germline PALB2 and somatic BRCA2 (Reiss 2021).","Two NICE appraisals cover olaparib in prostate cancer in England. TA887 recommends it as monotherapy for hormone-relapsed metastatic prostate cancer with BRCA1 or BRCA2 mutations that has progressed after a newer hormonal treatment; the recommendation is for BRCA specifically, not the wider homologous recombination repair panel. TA951 recommends it with abiraterone and prednisone or prednisolone for untreated hormone-relapsed metastatic prostate cancer in adults who cannot have or do not want chemotherapy, which is an unselected indication."],"brand":"Lynparza","modality":"Small-molecule PARP inhibitor","mechanism":"PARP1/2 inhibitor and trapper; synthetic lethality with HRD.","approvals":[{"region":"US","year":2014,"indication":"gBRCA ovarian cancer ≥3 lines"},{"region":"US","year":2018,"indication":"gBRCA HER2- metastatic breast cancer"},{"region":"US","year":2022,"indication":"Adjuvant gBRCA high-risk HER2- early breast cancer"},{"region":"EU","year":2019,"indication":"Germline BRCA1/2-mutated HER2-negative locally advanced or metastatic breast cancer after an anthracycline and a taxane (OlympiAD)","note":"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza"},{"region":"EU","year":2022,"indication":"Adjuvant treatment, alone or with endocrine therapy, of germline BRCA1/2-mutated HER2-negative high-risk early breast cancer after neoadjuvant or adjuvant chemotherapy (OlympiA)","note":"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza"},{"region":"UK","year":2023,"indication":"Adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy; NICE TA886 (10 May 2023) recommends within the marketing authorisation with a commercial arrangement","note":"https://www.nice.org.uk/guidance/ta886"},{"region":"UK","year":2025,"indication":"BRCA mutation-positive HER2-negative locally advanced or metastatic breast cancer after an anthracycline and a taxane; NICE TA1040 (12 February 2025) recommends with a commercial arrangement, the lowest-cost option to be used where talazoparib is also suitable","note":"https://www.nice.org.uk/guidance/ta1040"},{"region":"US","year":2019,"indication":"Maintenance treatment of deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of first-line platinum-based chemotherapy (POLO), with an FDA-approved companion diagnostic","note":"Lynparza label (openFDA), indication 1.6 and POLO study section: https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22LYNPARZA%22"},{"region":"EU","year":2020,"indication":"Maintenance treatment of germline BRCA1/2-mutated metastatic pancreatic adenocarcinoma that has not progressed after at least 16 weeks of platinum-based first-line chemotherapy; listed in the EMA Lynparza product information read on 24 September 2026 (extension of indication in 2020)","note":"https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza"}],"mechanismSteps":["Olaparib binds PARP1/2 at sites of single-strand DNA breaks","PARP is trapped on DNA and repair of single-strand breaks stops","Replication forks collide with trapped PARP and collapse into double-strand breaks","BRCA-deficient cells cannot repair the breaks by homologous recombination","Genomic catastrophe and apoptosis in tumour cells; normal cells with intact BRCA survive"],"dosing":{"route":"Oral","schedule":"300 mg twice daily; 1 year adjuvant (OlympiA); 2 years first-line ovarian maintenance; until progression otherwise","modifications":"200 mg BID for moderate renal impairment; hold for grade ≥3 anaemia; discontinue for MDS/AML or pneumonitis","monitoring":"Blood counts monthly; respiratory symptoms; embryo-fetal counselling","source":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa"},"toxicity":[{"event":"Nausea","anyGradePct":57,"grade3PlusPct":0.8,"source":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa","note":"OlympiA adjuvant, n=911"},{"event":"Fatigue","anyGradePct":42,"grade3PlusPct":1.8,"source":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa","note":"OlympiA adjuvant, n=911"},{"event":"Anaemia","anyGradePct":24,"grade3PlusPct":9,"source":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa","note":"OlympiA adjuvant, n=911"},{"event":"Vomiting","anyGradePct":23,"grade3PlusPct":0.7,"source":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa","note":"OlympiA adjuvant, n=911"},{"event":"Diarrhoea","anyGradePct":18,"grade3PlusPct":0.3,"source":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa","note":"OlympiA adjuvant, n=911"},{"event":"Leukopenia","anyGradePct":17,"grade3PlusPct":3,"source":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa","note":"OlympiA adjuvant, n=911"},{"event":"Neutropenia","anyGradePct":16,"grade3PlusPct":5,"source":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa","note":"OlympiA adjuvant, n=911"},{"event":"MDS/AML","anyGradePct":1.2,"source":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa","note":"Cumulative across trials; 54% fatal"},{"event":"Pneumonitis","anyGradePct":1,"source":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa","note":"OlympiA adjuvant, n=911"},{"event":"Venous thromboembolism (prostate)","anyGradePct":8,"source":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa","note":"OlympiA adjuvant, n=911"}],"access":[{"country":"US","reimbursement":"Medicare Part D (oral); commercial plans per formulary, often with prior authorisation","assistance":"https://www.astrazeneca-us.com/medicines/access-360","source":"https://www.cms.gov/medicare/payment/part-b-drugs/asp-pricing-files","asOf":"2026-09-06"},{"country":"UK","reimbursement":"NICE: recommended in ovarian maintenance (TA598, TA620), adjuvant gBRCA breast (TA886), metastatic breast (TA1100), prostate (TA887)","source":"https://www.nice.org.uk/guidance/published?ngt=Technology%20appraisal%20guidance","asOf":"2026-09-06"},{"country":"EU","reimbursement":"EMA approved across indications","asOf":"2026-09-06"}],"regulatoryEvents":[{"date":"2014-12-19","type":"accelerated-approval","region":"US","note":"gBRCA advanced ovarian cancer after ≥3 lines: first PARP inhibitor","source":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","indication":"Deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer after treatment with 3 or more lines of chemotherapy 2"},{"date":"2017-08-17","type":"conversion","region":"US","note":"Maintenance in platinum-sensitive recurrent ovarian cancer; tablet formulation","source":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","indication":"Deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer after treatment with 3 or more lines of chemotherapy 2"},{"date":"2018-01-12","type":"approval","region":"US","note":"gBRCA HER2-negative metastatic breast cancer (OlympiAD)","source":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"},{"date":"2018-12-19","type":"approval","region":"US","note":"First-line maintenance in BRCA-mutated ovarian cancer (SOLO-1)","source":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"},{"date":"2019-12-27","type":"approval","region":"US","note":"gBRCA metastatic pancreatic cancer maintenance (POLO)","source":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"},{"date":"2020-05-19","type":"approval","region":"US","note":"HRR-mutant mCRPC (PROfound)","source":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"},{"date":"2022-03-11","type":"approval","region":"US","note":"Adjuvant gBRCA high-risk HER2-negative early breast cancer (OlympiA)","source":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"},{"date":"2023-05-31","type":"approval","region":"US","note":"With abiraterone in BRCA-mutated mCRPC (PROpel)","source":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"}]},"route":"/drugs/olaparib/","neighbours":{"biomarker":[{"id":"brca-germline","kind":"biomarker","name":"Germline BRCA1/2 pathogenic variant (gBRCAm)","route":"/biomarkers/brca-germline/"},{"id":"hrr-gene-mutation","kind":"biomarker","name":"Homologous recombination repair gene mutation in prostate cancer","route":"/biomarkers/hrr-gene-mutation/"},{"id":"hrd-positive","kind":"biomarker","name":"HRD-positive (genomic instability score)","route":"/biomarkers/hrd-positive/"},{"id":"brca-somatic","kind":"biomarker","name":"Tumour (somatic or germline) BRCA1/2 mutation and HRR gene alterations","route":"/biomarkers/brca-somatic/"}],"cancer":[{"id":"advanced-recurrent-endometrial-cancer","kind":"cancer","name":"Advanced or recurrent endometrial cancer","route":"/cancers/advanced-recurrent-endometrial-cancer/"},{"id":"brca-palb2-pdac","kind":"cancer","name":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","route":"/cancers/brca-palb2-pdac/"},{"id":"brca-associated-tnbc","kind":"cancer","name":"BRCA-associated triple-negative breast cancer","route":"/cancers/brca-associated-tnbc/"},{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"},{"id":"high-grade-serous-ovarian-cancer","kind":"cancer","name":"High-grade serous ovarian cancer","route":"/cancers/high-grade-serous-ovarian-cancer/"},{"id":"hr-positive-early-high-risk","kind":"cancer","name":"High-risk early HR-positive breast cancer","route":"/cancers/hr-positive-early-high-risk/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"hr-positive-metastatic-post-cdk46","kind":"cancer","name":"HR-positive metastatic breast cancer after CDK4/6 inhibitors","route":"/cancers/hr-positive-metastatic-post-cdk46/"},{"id":"inflammatory-breast-cancer","kind":"cancer","name":"Inflammatory breast cancer","route":"/cancers/inflammatory-breast-cancer/"},{"id":"male-breast-cancer","kind":"cancer","name":"Male breast cancer","route":"/cancers/male-breast-cancer/"},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"},{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"endometrial-p53-abnormal","kind":"cancer","name":"p53-abnormal endometrial cancer, including uterine serous carcinoma","route":"/cancers/endometrial-p53-abnormal/"},{"id":"pancreatic-acinar-cell-carcinoma","kind":"cancer","name":"Pancreatic acinar cell carcinoma","route":"/cancers/pancreatic-acinar-cell-carcinoma/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"platinum-sensitive-ovarian-cancer","kind":"cancer","name":"Platinum-sensitive ovarian cancer","route":"/cancers/platinum-sensitive-ovarian-cancer/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"hrd-genomic-scar-scores","kind":"technology","name":"HRD genomic scar scores (GIS, LOH, HRDetect)","route":"/technologies/hrd-genomic-scar-scores/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"},{"id":"rad51-foci-assay","kind":"technology","name":"RAD51 foci assay (functional HRD test)","route":"/technologies/rad51-foci-assay/"},{"id":"st-johns-wort-interaction","kind":"technology","name":"St John's wort: an interaction to avoid","route":"/technologies/st-johns-wort-interaction/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"company":[{"id":"arcagy-gineco","kind":"company","name":"ARCAGY-GINECO","route":"/companies/arcagy-gineco/"},{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"breast-cancer-trials","kind":"company","name":"Breast Cancer Trials","route":"/companies/breast-cancer-trials/"},{"id":"big","kind":"company","name":"Breast International Group (BIG)","route":"/companies/big/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"},{"id":"nrg-oncology","kind":"company","name":"NRG Oncology","route":"/companies/nrg-oncology/"}],"term":[{"id":"brca-reversion-mutations","kind":"term","name":"BRCA reversion mutations","route":"/terms/brca-reversion-mutations/"},{"id":"genome-wide-loss-of-heterozygosity","kind":"term","name":"Genome-wide loss of heterozygosity (gLOH)","route":"/terms/genome-wide-loss-of-heterozygosity/"},{"id":"gbrca-mutation","kind":"term","name":"Germline BRCA mutation (gBRCA)","route":"/terms/gbrca-mutation/"},{"id":"hrd-in-breast-cancer","kind":"term","name":"Homologous recombination deficiency (HRD) in breast cancer","route":"/terms/hrd-in-breast-cancer/"},{"id":"inhibitor","kind":"term","name":"Inhibitor","route":"/terms/inhibitor/"},{"id":"idfs","kind":"term","name":"Invasive disease-free survival (iDFS)","route":"/terms/idfs/"},{"id":"maintenance-therapy","kind":"term","name":"Maintenance therapy","route":"/terms/maintenance-therapy/"},{"id":"pancreatic-cancer-uk-drug-access","kind":"term","name":"Pancreatic cancer drugs in England: NICE appraisals and the Cancer Drugs Fund (September 2026)","route":"/terms/pancreatic-cancer-uk-drug-access/"},{"id":"rejuv-second-platinum-and-parp-inhibitors","kind":"term","name":"Platinum drugs and PARP inhibitors: the newer leukaemia risk","route":"/terms/rejuv-second-platinum-and-parp-inhibitors/"},{"id":"prostate-uk-drug-approvals","kind":"term","name":"Prostate cancer drugs in England: what NICE recommends, and what it refuses","route":"/terms/prostate-uk-drug-approvals/"},{"id":"tnbc-residual-disease-decision","kind":"term","name":"Residual disease after neoadjuvant therapy in triple-negative breast cancer: the decision point","route":"/terms/tnbc-residual-disease-decision/"},{"id":"small-molecule","kind":"term","name":"Small molecule drug","route":"/terms/small-molecule/"},{"id":"somatic-mutation-theory","kind":"term","name":"Somatic mutation theory of cancer","route":"/terms/somatic-mutation-theory/"},{"id":"prostate-hrr-eligibility","kind":"term","name":"Who is eligible for a PARP inhibitor in prostate cancer, and why the gene matters","route":"/terms/prostate-hrr-eligibility/"}],"trial":[{"id":"nct02734004","kind":"trial","name":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.","route":"/trials/nct02734004/"},{"id":"nct06112379","kind":"trial","name":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","route":"/trials/nct06112379/"},{"id":"nct03459846","kind":"trial","name":"A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)","route":"/trials/nct03459846/"},{"id":"nct04683679","kind":"trial","name":"A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negat","route":"/trials/nct04683679/"},{"id":"nct07024784","kind":"trial","name":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN1","route":"/trials/nct07024784/"},{"id":"nct04858334","kind":"trial","name":"APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a","route":"/trials/nct04858334/"},{"id":"nct07005583","kind":"trial","name":"Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent","route":"/trials/nct07005583/"},{"id":"nct06686030","kind":"trial","name":"Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer","route":"/trials/nct06686030/"},{"id":"cupisco","kind":"trial","name":"CUPISCO","route":"/trials/cupisco/"},{"id":"nct04884360","kind":"trial","name":"D9319C00001- 1L OC Mono Global RCT","route":"/trials/nct04884360/"},{"id":"duo-e","kind":"trial","name":"DUO-E / GOG-3041 / ENGOT-EN10","route":"/trials/duo-e/"},{"id":"duo-o","kind":"trial","name":"DUO-O / ENGOT-ov46","route":"/trials/duo-o/"},{"id":"nct03742895","kind":"trial","name":"Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)","route":"/trials/nct03742895/"},{"id":"nct06525298","kind":"trial","name":"EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors","route":"/trials/nct06525298/"},{"id":"nct06909825","kind":"trial","name":"FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","route":"/trials/nct06909825/"},{"id":"i-spy-2","kind":"trial","name":"I-SPY 2","route":"/trials/i-spy-2/"},{"id":"nct06419179","kind":"trial","name":"Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extens","route":"/trials/nct06419179/"},{"id":"nct03784014","kind":"trial","name":"Molecular Profiling of Advanced Soft-tissue Sarcomas","route":"/trials/nct03784014/"},{"id":"pediatric-match","kind":"trial","name":"NCI-COG Pediatric MATCH (APEC1621)","route":"/trials/pediatric-match/"},{"id":"nct05485766","kind":"trial","name":"Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer","route":"/trials/nct05485766/"},{"id":"nct05522491","kind":"trial","name":"Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer","route":"/trials/nct05522491/"},{"id":"nct04042831","kind":"trial","name":"Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations","route":"/trials/nct04042831/"},{"id":"nct01874353","kind":"trial","name":"Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy","route":"/trials/nct01874353/"},{"id":"nct05222971","kind":"trial","name":"Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy","route":"/trials/nct05222971/"},{"id":"olympia","kind":"trial","name":"OlympiA","route":"/trials/olympia/"},{"id":"olympiad","kind":"trial","name":"OlympiAD","route":"/trials/olympiad/"},{"id":"paola-1","kind":"trial","name":"PAOLA-1 / ENGOT-ov25","route":"/trials/paola-1/"},{"id":"partner","kind":"trial","name":"PARTNER","route":"/trials/partner/"},{"id":"nct07486687","kind":"trial","name":"Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy","route":"/trials/nct07486687/"},{"id":"nct05623319","kind":"trial","name":"Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)","route":"/trials/nct05623319/"},{"id":"nct05093231","kind":"trial","name":"Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer","route":"/trials/nct05093231/"},{"id":"nct06245889","kind":"trial","name":"PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC","route":"/trials/nct06245889/"},{"id":"nct06915025","kind":"trial","name":"Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Pat","route":"/trials/nct06915025/"},{"id":"nct03334617","kind":"trial","name":"Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy","route":"/trials/nct03334617/"},{"id":"phoenix","kind":"trial","name":"PHOENIX DDR/Anti-PD-L1","route":"/trials/phoenix/"},{"id":"nct04624204","kind":"trial","name":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-","route":"/trials/nct04624204/"},{"id":"plasmamatch","kind":"trial","name":"plasmaMATCH","route":"/trials/plasmamatch/"},{"id":"polo","kind":"trial","name":"POLO","route":"/trials/polo/"},{"id":"profound","kind":"trial","name":"PROfound","route":"/trials/profound/"},{"id":"propel","kind":"trial","name":"PROpel","route":"/trials/propel/"},{"id":"nct07453394","kind":"trial","name":"QLS5132 Combination Therapy in Advanced Solid Tumors","route":"/trials/nct07453394/"},{"id":"rainbo","kind":"trial","name":"RAINBO","route":"/trials/rainbo/"},{"id":"nct04421963","kind":"trial","name":"Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib","route":"/trials/nct04421963/"},{"id":"solo-1","kind":"trial","name":"SOLO-1","route":"/trials/solo-1/"},{"id":"nct05898399","kind":"trial","name":"Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)","route":"/trials/nct05898399/"},{"id":"nct03775486","kind":"trial","name":"Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)","route":"/trials/nct03775486/"},{"id":"nct05933265","kind":"trial","name":"Study of LP-184 in Patients With Advanced Solid Tumors","route":"/trials/nct05933265/"},{"id":"nct05498155","kind":"trial","name":"Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer","route":"/trials/nct05498155/"},{"id":"nct02861573","kind":"trial","name":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","route":"/trials/nct02861573/"},{"id":"nct04380636","kind":"trial","name":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","route":"/trials/nct04380636/"},{"id":"nct05171816","kind":"trial","name":"Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)","route":"/trials/nct05171816/"},{"id":"nct01081951","kind":"trial","name":"Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitax","route":"/trials/nct01081951/"},{"id":"nct06353386","kind":"trial","name":"Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)","route":"/trials/nct06353386/"},{"id":"tapur","kind":"trial","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","route":"/trials/tapur/"},{"id":"nct05128734","kind":"trial","name":"Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)","route":"/trials/nct05128734/"},{"id":"nct03330847","kind":"trial","name":"To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.","route":"/trials/nct03330847/"},{"id":"nct04644289","kind":"trial","name":"WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC","route":"/trials/nct04644289/"}],"paper":[{"id":"paper-hu-germline-mutations-pancreatic-cancer-risk-jama-2018","kind":"paper","name":"Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer","route":"/key-papers/paper-hu-germline-mutations-pancreatic-cancer-risk-jama-2018/"},{"id":"paper-duo-e-jco-2023","kind":"paper","name":"DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer","route":"/key-papers/paper-duo-e-jco-2023/"},{"id":"paper-bedrosian-asco-sso-germline-testing-breast-jco-2024","kind":"paper","name":"Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology guideline","route":"/key-papers/paper-bedrosian-asco-sso-germline-testing-breast-jco-2024/"},{"id":"paper-couch-tnbc-germline-17-genes-jco-2015","kind":"paper","name":"Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer","route":"/key-papers/paper-couch-tnbc-germline-17-genes-jco-2015/"},{"id":"paper-asco-hereditary-breast-cancer-guideline-jco-2020","kind":"paper","name":"Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline","route":"/key-papers/paper-asco-hereditary-breast-cancer-guideline-jco-2020/"},{"id":"paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020","kind":"paper","name":"Metastatic Pancreatic Cancer: ASCO Guideline Update","route":"/key-papers/paper-asco-metastatic-pancreatic-cancer-guideline-update-jco-2020/"},{"id":"paper-olympia-nejm-2021","kind":"paper","name":"OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer","route":"/key-papers/paper-olympia-nejm-2021/"},{"id":"paper-olympiad-nejm-2017","kind":"paper","name":"OlympiAD: olaparib versus chemotherapy in metastatic breast cancer with a germline BRCA mutation","route":"/key-papers/paper-olympiad-nejm-2017/"},{"id":"paper-olympia-overall-survival-ann-oncol-2022","kind":"paper","name":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer","route":"/key-papers/paper-olympia-overall-survival-ann-oncol-2022/"},{"id":"paper-paola-1-nejm-2019","kind":"paper","name":"PAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours","route":"/key-papers/paper-paola-1-nejm-2019/"},{"id":"paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022","kind":"paper","name":"POLO final overall survival: maintenance olaparib versus placebo in germline BRCA-mutated metastatic pancreatic cancer","route":"/key-papers/paper-polo-overall-survival-olaparib-gbrca-pancreatic-jco-2022/"},{"id":"paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019","kind":"paper","name":"POLO: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","route":"/key-papers/paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019/"},{"id":"paper-profound-nejm-2020","kind":"paper","name":"PROfound: olaparib for metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations","route":"/key-papers/paper-profound-nejm-2020/"},{"id":"paper-solo-1-nejm-2018","kind":"paper","name":"SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer","route":"/key-papers/paper-solo-1-nejm-2018/"},{"id":"paper-olympia-6-year-update-ann-oncol-2026","kind":"paper","name":"Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: updated results from the OlympiA phase III trial","route":"/key-papers/paper-olympia-6-year-update-ann-oncol-2026/"},{"id":"paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015","kind":"paper","name":"TOPARP-A: DNA-repair defects and olaparib in metastatic prostate cancer","route":"/key-papers/paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015/"}],"pairing":[{"id":"germline-to-parp","kind":"pairing","name":"Germline BRCA test → adjuvant PARP inhibitor","route":"/pairings/germline-to-parp/"},{"id":"parp-plus-arpi","kind":"pairing","name":"PARP inhibitor + AR pathway inhibitor (prostate)","route":"/pairings/parp-plus-arpi/"},{"id":"parp-plus-bevacizumab","kind":"pairing","name":"PARP inhibitor + bevacizumab maintenance (HRD-positive)","route":"/pairings/parp-plus-bevacizumab/"}],"idea":[{"id":"idea-tr2-hrd-functional-standard","kind":"idea","name":"A functional test for homologous recombination deficiency validated across laboratories","route":"/ideas/idea-tr2-hrd-functional-standard/"},{"id":"idea-tnbc-uk-trial-access-and-germline-testing-audit","kind":"idea","name":"A UK audit of trial access and germline testing uptake in triple-negative breast cancer","route":"/ideas/idea-tnbc-uk-trial-access-and-germline-testing-audit/"},{"id":"idea-ctdna-guided-parp-duration","kind":"idea","name":"ctDNA-guided duration of PARP maintenance","route":"/ideas/idea-ctdna-guided-parp-duration/"},{"id":"idea-cost-shorter-course-trials","kind":"idea","name":"Fund trials that test shorter courses of the most expensive adjuvant drugs","route":"/ideas/idea-cost-shorter-course-trials/"},{"id":"idea-molecular-class-adjuvant-endometrial","kind":"idea","name":"Molecular-class-directed adjuvant therapy in endometrial cancer","route":"/ideas/idea-molecular-class-adjuvant-endometrial/"},{"id":"idea-reg-indication-specific-pricing","kind":"idea","name":"Pay a different price for the same cancer drug depending on the indication","route":"/ideas/idea-reg-indication-specific-pricing/"},{"id":"idea-prostate-randomise-the-sequence-not-only-the-drugs","kind":"idea","name":"Randomise the order of treatment, not only the drugs: a strategy platform for metastatic prostate cancer","route":"/ideas/idea-prostate-randomise-the-sequence-not-only-the-drugs/"},{"id":"idea-prostate-hrr-testing-at-metastatic-diagnosis","kind":"idea","name":"Test every man for DNA repair faults on the day his prostate cancer is found to have spread, not three treatments later","route":"/ideas/idea-prostate-hrr-testing-at-metastatic-diagnosis/"}],"roadmap":[{"id":"pancreatic-roadmap","kind":"roadmap","name":"Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question","route":"/roadmaps/pancreatic-roadmap/"},{"id":"targeted-therapy-roadmap","kind":"roadmap","name":"Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall","route":"/roadmaps/targeted-therapy-roadmap/"},{"id":"tnbc-history","kind":"roadmap","name":"TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line","route":"/roadmaps/tnbc-history/"},{"id":"tnbc-roadmap","kind":"roadmap","name":"Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem","route":"/roadmaps/tnbc-roadmap/"}],"person":[{"id":"alan-ashworth","kind":"person","name":"Alan Ashworth","route":"/people/alan-ashworth/"},{"id":"amit-oza","kind":"person","name":"Amit M. Oza","route":"/people/amit-oza/"},{"id":"andrew-tutt","kind":"person","name":"Andrew Tutt","route":"/people/andrew-tutt/"},{"id":"charles-geyer","kind":"person","name":"Charles E. Geyer Jr.","route":"/people/charles-geyer/"},{"id":"eileen-oreilly","kind":"person","name":"Eileen M. O'Reilly","route":"/people/eileen-oreilly/"},{"id":"hedy-kindler","kind":"person","name":"Hedy L. Kindler","route":"/people/hedy-kindler/"},{"id":"isabelle-ray-coquard","kind":"person","name":"Isabelle Ray-Coquard","route":"/people/isabelle-ray-coquard/"},{"id":"jean-abraham","kind":"person","name":"Jean Abraham","route":"/people/jean-abraham/"},{"id":"johann-de-bono","kind":"person","name":"Johann de Bono","route":"/people/johann-de-bono/"},{"id":"jonathan-ledermann","kind":"person","name":"Jonathan A. Ledermann","route":"/people/jonathan-ledermann/"},{"id":"kathleen-moore","kind":"person","name":"Kathleen N. Moore","route":"/people/kathleen-moore/"},{"id":"maha-hussain","kind":"person","name":"Maha Hussain","route":"/people/maha-hussain/"},{"id":"sherry-lansing","kind":"person","name":"Sherry Lansing","route":"/people/sherry-lansing/"},{"id":"susan-domchek","kind":"person","name":"Susan M. Domchek","route":"/people/susan-domchek/"},{"id":"talia-golan","kind":"person","name":"Talia Golan","route":"/people/talia-golan/"},{"id":"thomas-helleday","kind":"person","name":"Thomas Helleday","route":"/people/thomas-helleday/"},{"id":"ursula-matulonis","kind":"person","name":"Ursula A. Matulonis","route":"/people/ursula-matulonis/"}],"institution":[{"id":"chum","kind":"institution","name":"Centre hospitalier de l'Université de Montréal (CHUM)","route":"/institutions/chum/"},{"id":"guys-st-thomas","kind":"institution","name":"Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre","route":"/institutions/guys-st-thomas/"},{"id":"sheba","kind":"institution","name":"Sheba Medical Center","route":"/institutions/sheba/"},{"id":"stephenson-oklahoma","kind":"institution","name":"Stephenson Cancer Center, OU Health","route":"/institutions/stephenson-oklahoma/"},{"id":"icr-london","kind":"institution","name":"The Institute of Cancer Research","route":"/institutions/icr-london/"},{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","route":"/institutions/royal-marsden/"}],"pathway":[{"id":"ar-signaling","kind":"pathway","name":"Androgen receptor signalling","route":"/pathways/ar-signaling/"},{"id":"base-excision-repair-parp","kind":"pathway","name":"Base excision repair, PARP & alkylation damage","route":"/pathways/base-excision-repair-parp/"},{"id":"breast-cancer-signalling","kind":"pathway","name":"Breast cancer (KEGG map)","route":"/pathways/breast-cancer-signalling/"},{"id":"ddr","kind":"pathway","name":"DNA damage response & homologous recombination","route":"/pathways/ddr/"},{"id":"homologous-recombination-repair","kind":"pathway","name":"Double-strand break repair: HR versus end joining","route":"/pathways/homologous-recombination-repair/"},{"id":"oncogene-activation-two-hit","kind":"pathway","name":"Drivers, passengers & the two-hit model","route":"/pathways/oncogene-activation-two-hit/"},{"id":"mutagenesis-signatures","kind":"pathway","name":"Mutagenesis & mutational signatures","route":"/pathways/mutagenesis-signatures/"},{"id":"pancreatic-cancer-signalling","kind":"pathway","name":"Pancreatic cancer (KEGG map)","route":"/pathways/pancreatic-cancer-signalling/"},{"id":"prostate-cancer-signalling","kind":"pathway","name":"Prostate cancer (KEGG map)","route":"/pathways/prostate-cancer-signalling/"},{"id":"synthetic-lethality-map","kind":"pathway","name":"Synthetic lethality: paired dependencies","route":"/pathways/synthetic-lethality-map/"}],"drug":[{"id":"bracanalysis-cdx","kind":"drug","name":"BRACAnalysis CDx","route":"/drugs/bracanalysis-cdx/"},{"id":"iniparib","kind":"drug","name":"Iniparib","route":"/drugs/iniparib/"},{"id":"mychoice-cdx","kind":"drug","name":"myChoice CDx","route":"/drugs/mychoice-cdx/"}],"bottleneck":[{"id":"b-hereditary-risk","kind":"bottleneck","name":"Inherited risk is mostly unidentified","route":"/bottlenecks/b-hereditary-risk/"}]}}